A Technology Development Roadmap for a Near-Term Probe-Class X-ray Astrophysics Mission

This document presents a roadmap, including proposed budget and schedule, for maturing the instrumentation needed for an X-ray astrophysics Probe-class mission. The Physics of the Cosmos (PCOS) Program Office was directed to create this roadmap following the December 2012 NASA Astrophysics Implementation Plan (AIP). Definition of this mission is called for in the AIP, with the possibility of selection in 2015 for a start in 2017. The overall mission capabilities and instrument performance requirements were defined in the 2010 Astronomy and Astrophysics Decadal Survey report, New Worlds, New Horizons in Astronomy and Astrophysics (NWNH), in connection with the highly ranked International X-ray Observatory (IXO). In NWNH, recommendations were provided regarding the size of, and instrumentation needed by, the next large X-ray observatory. Specifically, the key instrumental capability would be an X-ray calorimeter spectrometer at the focus of a large mirror with angular resolution of 10 arc seconds (arcsec) or better. If possible, a grating spectrometer should also be incorporated into the instrument complement. In response to these recommendations, four instrumentation technologies are included in this roadmap. Three of these are critical for an X-ray mission designed to address NWNH questions: segmented X-ray mirrors, transition edge sensor calorimeters, and gratings. Two approaches are described for gratings, which represent the least mature technology and thus most in need of a parallel path for risk reduction. Also, while current CCD detectors would likely meet the mission needs for grating spectrum readout, specific improvements are included as an additional approach for achieving the grating system effective area requirement. The technical steps needed for these technologies to attain technology readiness levels (TRL) of 5 and 6 are described, as well as desirable modest risk reduction steps beyond TRL-6. All of the technology development efforts are currently funded through the NASA Physics of the Cosmos (PCOS) Strategic Astrophysics Technology (SAT) program; some through the end of FY13, others though FY14. These technology needs are those identified as critical for a near-term mission and briefly described in the 2012 NASA X-ray Mission Concepts Study. This Technology Development Roadmap (TDR) provides a more complete description of each, updates the status, and describes the steps to mature them. For each technology, a roadmap is presented for attaining TRL-6 by 2020 at the latest, and 2018 for most. The funding required for each technology to attain TRL-5 and TRL-6 is presented and justified through a description of the steps needing completion. The total funding required for these technologies to reach TRL-6 is relatively modest, and is consistent with the planned PCOS SAT funding over the next several years. The approximate annual cost through 2018 is $8M. The total cost for all technologies to be matured is$62M (including funding already awarded for FY13 and FY14). This can be contrasted to the $180M recommended by NWNH for technology development for IXO, primarily for the maturation of the mirror technology. The technology described in Section 3 of this document is exclusively that needed for a near-term Probe-class mission, to start in 2017, or for a mission that can be recommended by the next Decadal survey committee for an immediate start. It is important to note that there are other critical X-ray instrumentation technologies under development that are less mature than the ones discussed here, but are essential for a major X-ray mission that might start in the late 2020s. These technologies, described briefly in Section 4, are more appropriately funded through the Astronomy and Physics Research and Analysis (APRA) program

Micromechanical Properties of Injection-Molded Starch–Wood Particle Composites

The micromechanical properties of injection molded starch–wood particle composites were investigated as a function of particle content and humidity conditions. The composite materials were characterized by scanning electron microscopy and X-ray diffraction methods. The microhardness of the composites was shown to increase notably with the concentration of the wood particles. In addition,creep behavior under the indenter and temperature dependence were evaluated in terms of the independent contribution of the starch matrix and the wood microparticles to the hardness value. The influence of drying time on the density and weight uptake of the injection-molded composites was highlighted. The results revealed the role of the mechanism of water evaporation, showing that the dependence of water uptake and temperature was greater for the starch–wood composites than for the pure starch sample. Experiments performed during the drying process at 70°C indicated that the wood in the starch composites did not prevent water loss from the samples.Peer reviewe

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

This article contains supplemental material online at http://cjasn. asnjournals.org/lookup/suppl/doi:10.2215/CJN.07730814/-/ DCSupplemental.BACKGROUND AND OBJECTIVES: The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older (≥65 years, n=1005) and younger (3-fold higher in younger relative to older patients and were more frequent in patients randomized to placebo. In older patients, the adjusted relative hazard (95% confidence interval) for the primary composite (CV) end point (cinacalcet versus placebo) was 0.70 (0.60 to 0.81); in younger patients, the relative hazard was 0.97 (0.86 to 1.09). Corresponding adjusted relative hazards for mortality were 0.68 (0.51 to 0.81) and 0.99 (0.86 to 1.13). Reduction in the risk of severe unremitting HPT was similar in both groups. CONCLUSIONS: In the EVOLVE trial, cinacalcet decreased the risk of death and of major CV events in older, but not younger, patients with moderate to severe HPT who were receiving hemodialysis. Effect modification by age may be partly explained by differences in underlying CV risk and differential application of cointerventions that reduce parathyroid hormone.The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial was funded by Amgen